Citius Pharmaceuticals Stock (NASDAQ:CTXR)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$1.67

52W Range

$0.65 - $26.25

50D Avg

$1.23

200D Avg

$3.04

Market Cap

$17.21M

Avg Vol (3M)

$2.67M

Beta

1.23

Div Yield

-

CTXR Company Profile


Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

23

IPO Date

Oct 02, 2014

Website

CTXR Performance


CTXR Financial Summary


Sep 24Sep 23Sep 22
Revenue---
Operating Income-$-36.73M$-33.32M
Net Income$-39.43M$-32.54M$-33.64M
EBITDA-$-36.73M$-32.88M
Basic EPS-$-0.23$-0.23
Diluted EPS-$-0.22$-0.23

Fiscal year ends in Sep 24 | Currency in USD

Peer Comparison


TickerCompany
OTLKOutlook Therapeutics, Inc.
HRTXHeron Therapeutics, Inc.
TNXPTonix Pharmaceuticals Holding Corp.
ASRTAssertio Holdings, Inc.
ATOSAtossa Therapeutics, Inc.
HOOKHOOKIPA Pharma Inc.
TRAWTraws Pharma, Inc.